SCHEMBL10003734

SCHEMBL10003734

CCc1nc2c(cc1-c1ccccn1)c(OCC(F)(F)F)c(C(=O)O)n2C

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 2/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ CYP2C19 P33261 1/20 0.35
▸ EIF4EBP1 Q13541 1/20 0.34
▸ HCRTR1 O43613 1/20 0.34
▸ HCRTR2 O43614 1/20 0.34
▸ PPARG P37231 1/20 0.33
▸ PPARD Q03181 1/20 0.33
▸ PPARA Q07869 1/20 0.33
▸ S1PR1 P21453 1/20 0.33
▸ S1PR3 Q99500 1/20 0.33
▸ NPC1 O15118 2/20 0.33
▸ RAB9A P51151 2/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ HSD17B10 Q99714 2/20 0.33
▸ METAP2 P50579 1/20 0.33
▸ FFAR1 O14842 1/20 0.33
▸ MAT2A P31153 1/20 0.33
▸ PAX8 Q06710 1/20 0.33
▸ POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10003975 0.90 RAB9A (0.42) CYP1A2CYP2C9CYP2C19HCRTR1NPC1
SCHEMBL10003096 0.88 GRIA2 (0.35) HCRTR1HCRTR2NPC1RAB9AALDH1A1
SCHEMBL10003464 0.86 GRIA2 (0.39) HCRTR1HCRTR2ALDH1A1HSD17B10UGCG
SCHEMBL10003154 0.85 PDE3B (0.38) ALDH1A1HSD17B10METAP2SCN9AKDM4E
SCHEMBL10004257 0.84 KDM4E (0.38) HCRTR1HCRTR2ALDH1A1HSD17B10SCN9A
SCHEMBL10003113 0.84 CCKAR (0.37) NPC1SCN9A
SCHEMBL10003039 0.84 SCN9A (0.41) HCRTR1HCRTR2ALDH1A1HSD17B10PAX8
SCHEMBL10003244 0.83 PTPN11 (0.39) PPARGPPARASCN9A
SCHEMBL10002905 0.83 GRIA2 (0.38) ALDH1A1POLBMAPTSCN9AMEN1
SCHEMBL10003383 0.83 ALPI (0.35) PPARGPPARASCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2471789-B9 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2015-03-25 — — EP disclosed
EP-2471789-B1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2014-09-17 — — EP disclosed
US-8486965-B2 Pyrrolo[2,3-b]pyridine derivative and use thereof for treatment of cancer TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-07-16 — — US disclosed
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-08-30 — — US disclosed
EP-2471789-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2012-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220569-A1 FUSED HETEROCYCLIC RING DERIVATIVE AND USE THEREOF SMO, GLI1, SHH CYP1A2 1170/4885CYP2C9 1142/4885CYP2C19 1348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback